Quantbot Technologies LP Increases Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Quantbot Technologies LP raised its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 230.5% during the third quarter, Holdings Channel.com reports. The fund owned 72,351 shares of the life sciences company’s stock after purchasing an additional 50,459 shares during the quarter. Quantbot Technologies LP’s holdings in Integra LifeSciences were worth $1,315,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of IART. CWM LLC lifted its stake in Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 425 shares during the period. Blue Trust Inc. lifted its position in shares of Integra LifeSciences by 100.5% in the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 444 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Integra LifeSciences by 7.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,454 shares of the life sciences company’s stock valued at $421,000 after purchasing an additional 1,010 shares in the last quarter. KBC Group NV increased its position in shares of Integra LifeSciences by 65.2% during the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after buying an additional 1,120 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its stake in Integra LifeSciences by 58.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock worth $136,000 after buying an additional 1,711 shares in the last quarter. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Price Performance

IART opened at $24.58 on Friday. Integra LifeSciences Holdings Co. has a 1 year low of $16.81 and a 1 year high of $45.42. The stock has a 50-day moving average price of $20.77 and a 200-day moving average price of $24.00. The firm has a market cap of $1.90 billion, a PE ratio of -273.08, a P/E/G ratio of 0.83 and a beta of 1.08. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.02. The firm had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business’s revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.76 earnings per share. Sell-side analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IART has been the topic of a number of research analyst reports. Bank of America reduced their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a report on Monday, October 7th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Truist Financial dropped their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Finally, Citigroup upped their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $24.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.